Your SlideShare is downloading. ×
Pan xiao
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Evodiamine isolated from Evodia rutaecarpa as human topoisomerase catalytic inhibitor Xiaobei Pan1 , Janet M. Hartley2 , John A. Hartley2 , Kenneth N White1 , Zhengtao Wang1,3 , S. W. Annie Bligh1 1 Institute for Health Research and Policy, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK 2 Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, University College London, Paul O’Gorman Building, London, UK 3 The MOE Key Laboratory for Standardization of Chinese Medicines and the SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Zhangjiang Hi-tech Park, Shanghai 201210, China Introduction  Topoisomerase (Fig. 1) is an enzyme, which can relieve torsional stress in DNA.  Topoisomerase I and II cleave the single and double stranded DNA, respectively.  Since camptothecin was found as a topoisomerase inhibitor, a number of semi- synthetic compounds were successfully developed and used to treat cancer.  Evodia rutaecarpa (Fig. 2) is a Chinese herbal medicinal plant that has been used to treat gastrointestinal disorders, bacterial infection & inflammation-related disorders.  Evodiamine isolated from Evodia rutaecarpa is cytotoxic to several cancer cell lines. Aims and Objectives  To isolate quinoline alkaloids from the Evodia and structure elucidation  To study their potential cytotoxicity, inhibitory activity of topoisomerase I and II, and catalytic mechanisms. Methods  Alkaloids were isolated using reverse-phase HPLC and the structures were elucidated by 1-D, 2-D NMR spectroscopy and mass spectrometry.  Their cytotoxicities were determined using MTT-based assay.  Topoisomerase (Topo) inhibitory activities were studied using Topo I relaxation and Topo II decatanation assay.  Comet assay and cell cycle distribution study were carried out by flow cytometry. Results and Discussion  Eight alkaloids were isolated from Evodia, of which evodiamine (Fig. 3) showed the most potent activity against human leukemia K562 and THP-1 cell lines (IC50 34.35 µM and 90.87 µM respectively.)  Evodiamine is an inhibitor for both human Topo I and Topo II (Fig. 4).  It did not induce DNA strand breaks at the cellular level (Fig. 5) and arrested cell growth at the G2/M phase in the cell cycle. N H N N O2 3 5 6 78 9 10 11 12 13 15 16 17 18 19 20 21 H H3C Conclusion Evodiamine was found to be a dual inhibitor for both topoisomerase I and II with potent cytotoxicity against human leukemia cell lines. Figure 1. Structure of topoisomerase Figure 2. Evodia rutaecarpa Figure 3. Structure of Evodiamine Figure 4. IC50 of evodiamine against human Topo I (A, C) using relaxation assay and Topo II (B, D) using decatanation assayFigure 5. The comet assay did not detect DNA strand breaks induced by evodiamine Acknowledgement X.Pan thanks the Department of Human Science at London Metropolitan University for a student bursary.